Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.99 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL31326687 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL31725676 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4445 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4444 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL122984 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4659664 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20185623 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL2217102 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20204237 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL29462666 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | claimed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | claimed |
| EP-3934634-B1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | UNIV MICHIGAN REGENTS (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| EP-4159204-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-4159205-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040152632-A1 | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome | WYETH (US) | 2004-08-05 | — | — | US | disclosed |
| US-20040053946-A1 | Cancer treatment method | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1353693-A2 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | GLAXO GROUP LIMITED (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-5385842-A | Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | TOP2A 1603/4885MEN1 2033/4885THRB 1567/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TOP2A 1172/4885MEN1 3875/4885THRB 3806/4885 |
| US-20040053946-A1 | Cancer treatment method | TP53, HNMT, TOP2B | TOP2A 4/4885MEN1 582/4885THRB 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.